Frontlight ResearchEarly access
Active, not recruitingNo phase
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
Key facts
- Who runs it
- Hangzhou Endonom Medtech Co., Ltd.
- Where
- China29 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 120 people enrolled
- Started
- 25 Dec 2020
- Expected to end
- 25 Dec 2026
- Type of study
- Interventional
- Treatments tested
- WeFlow-Tbranch Stent Graft System
- Record updated
- 30 April 2024
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Patients aged 18 to 80 years old, no gender limitation
- Able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the patient him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol
- Diagnosed as Stanford type B aortic dissection and needed reconstruction of the left subclavian artery
- The diameter of the proximal anchoring area (the aorta at the posterior edge of the left common carotid artery) range: 18~42mm
- The length of the proximal anchoring area (the distance from the rear edge of the left common carotid artery opening to the first breach) ≥15mm
- The distance between the left common carotid artery and the left subclavian artery ≥5mm
- The distance between the left vertebral artery and the opening of the left subclavian artery is ≥15mm, the diameter of the starting part of the left subclavian artery is 6~20mm
- With proper femoral artery, iliac artery, and brachial artery access, endovascular treatment of the aorta can be performed
Who cannot take part
- Participated in clinical trials of other drugs or devices during the same period
- Contraindications to antiplatelet drugs and anticoagulants
- The same operation requires intervention in other vascular diseases (such as coronary artery, renal artery, superior mesenteric artery, etc.), and the postoperative drug treatment plan is therefore affected
- Allergic to contrast agents, anesthetics, patches, and delivery materials
- History of myocardial infarction, TIA or cerebral infarction within the past 3 months
- Life expectancy is less than 12 months (such as advanced malignant tumors)
- Acute systemic infection
- Severe liver, kidney, lung, and heart function abnormalities before surgery [Serum creatinine exceeds 2 times the upper limit of normal; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds 5 times the upper limit of normal; Serum total bilirubin (STB) more than 2 times the upper limit of normal; Left ventricular ejection fraction is lower than normal by cardiac color Doppler ultrasound examination]
- Pregnant, breastfeeding or cannot contraception during the trial period
- Cannot tolerate anesthesia
- True/false thoracic aortic aneurysm
- Severe stenosis or calcification in the anchoring area at the proximal end of the stent, easily lead to the stent graft difficult adherent
- Investigator judged that not suitable for interventional treatment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a prospective, multiple center study to evaluate the safety and effectiveness of WeFlow-Tbranch single embedded branch thoracic aorta stent graft system manufactured by EndoNom Medtech (Hangzhou) Co., Ltd.
The group in the trial
- WeFlow-Tbranch Stent Graft SystemTreatment being tested
Participants will be treated with WeFlow-Tbranch Stent Graft System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 April 2024